STAGE™ Platform

• • Enhances MRI brain scan quality by improving visualization and clarity.
  • Integrates seamlessly with a wide range of MRI machines, including all 1.5T and 3T magnets.
  • Offers up to 40% faster scanning times, adding 90–120 minutes of scan time per machine per day.
  • Relies on MRI physics rather than AI, providing fully sampled, 3D data.
  • Applicable in various medical conditions such as tumor detection, multiple sclerosis, traumatic brain injuries, stroke detection, aging and dementia, and Parkinson’s disease.
  • Utilized in enhancing gray-white matter contrast, facilitating efficient reads, and reducing scan times by 30%.
  • Capable of replacing standard, longer-duration GRE and SWI scans due to high sensitivity to cerebral microbleeds and thrombus.
  • Improves the visualization and quantification of key brain areas, aiding in the early detection of diseases and the planning of treatments like deep brain stimulation (DBS).

Tumor Detection, Metastasis & Radiation Therapy: The STAGE™ platform offers multiparametric maps that significantly improve the ability to distinguish between tumor tissues, alterations in adjacent tissues, and blood products associated with tumors. 

Moreover, STAGE™ facilitates the assessment of T1 and PD properties, which are indicative of changes in water content and the presence of leaky blood vessels. It also enhances the detection of cerebral microbleeds, often a consequence of radiation therapy.

Multiple Sclerosis: Lesions from Multiple Sclerosis, impacting the central nervous system, are noted to occur around the brain and spine, particularly in areas surrounding the veins.

The multiparametric maps produced by STAGE™ significantly improve the visibility of these lesions within the white matter. They also reveal various changes, including fluctuations in blood flow, inflammation levels, water content, susceptibility, iron deposition, tissue shrinkage, demyelination, and abnormal blood vessels linked with the lesions.

Traumatic Brain Injury: STAGE™ produces exceptionally detailed images of lesions and vascular damage caused by trauma, which might go undetected in standard or low-resolution scans.

This technology is especially effective for the precise visualization of cerebral microbleeds, injuries to the medullary veins, shearing damage, and subarachnoid hemorrhage.

Stroke Detection: STAGE™ can substitute traditional, lengthier GRE and SWI scans thanks to its heightened sensitivity to cerebral micro-bleeds and thrombi.

Additionally, it effectively illustrates features like asymmetrically prominent cortical veins, oxygenation levels in the surrounding penumbra of a stroke, focal stroke lesions, disruptions in angiography flow, and arterial irregularities in the Circle of Willis. The standardized outputs of STAGE™ also facilitate consistent baseline assessments and tracking changes over time through longitudinal image comparisons.

Aging & Dementia: STAGE™ enhances visualization and measurement of crucial brain regions, such as white matter/gray matter contrast and cerebrospinal fluid, neurovascular lesions, hemosiderin deposits, and the distinction between mineralization and hemorrhage.

It enables the visual identification of dephasing due to calcification or bleeding. Additionally, the T1 Map and T1W outputs of STAGE™ offer improved contrast differentiation among various tissue types.

Parkinson’s Disease: STAGE™ delivers both qualitative and quantitative results for the visualization of essential biomarkers. Its multiparametric maps, including QSM and R2*, are instrumental in quantifying iron content in deep gray matter structures and visualizing neuromelanin within the midbrain.

Additionally, STAGE™ offers automatic segmentation of brain structures. These capabilities are particularly valuable for early disease detection and guiding the surgical positioning of deep brain stimulation (DBS) devices.